| |
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Save up to $500 with Early Bird Rates.Register Now! 
|
|
Today’s Big NewsAug 1, 2024 |
|
September 30- October 1, 2024 | Boston, MA Join the Fierce Biotech Summit to explore biotech's recovery and future. This two-day event features leaders discussing biotech IPOs, cell therapy, regulatory challenges, and strategic innovations. Connect with experts and gain valuable industry insights. Save up to $500 with Early Bird Rates. Register Now! 
|
|
| By Annalee Armstrong While Biogen’s pharma peers are hunting for late-stage assets with little risk, CEO Chris Viehbacher wants to bring in more early-stage medicines, arguing that there’s more shareholder value to be had the earlier a company can get in. |
|
|
|
By Gabrielle Masson As biotechs attempt to turn a fresh page in August, at least three companies have shed staff in attempts to forge on. |
By Darren Incorvaia After more than 30 years, gene therapy trailblazer James Wilson M.D., Ph.D., is leaving the University of Pennsylvania to spearhead two new biotechs. |
Sponsored by InMed Pharmaceuticals InMed Pharmaceuticals recently released preclinical data indicating its proprietary, small molecule compound, INM-901, targets multiple biological pathways associated with Alzheimer’s disease. |
|
Maximize Your Brand Exposure From brand awareness to lead generation, our tailored marketing solutions help you achieve your objectives. Get noticed, start conversations, and drive demand with Fierce Biotech. Learn more now. 
|
|
By Annalee Armstrong Biogen has handed back rights to an early Alzheimer’s disease program to Denali Therapeutics, leaving a large hole in the biotech’s collaboration revenue stream. |
By Nick Paul Taylor Another of Ionis’ key midphase readouts has fallen short of expectations, prompting the biotech to stop studying the Roche-partnered candidate in an advanced form of age-related macular degeneration. |
By Nick Paul Taylor ALX Oncology’s phase 2 gastric cancer response rate has weakened. After seeing its CD47 blocker easily beat control over the first half of the trial, the biotech reported a much closer fight in the second part of the study—and investors were quick to send the stock spiraling downward. |
By Darren Incorvaia Since its passage in August 2022, the Inflation Reduction Act has attracted criticism and even derision from biopharma leaders because it gives Medicare the ability to negotiate drug prices. But new studies suggest that fears the IRA will hurt innovation are overblown. |
By James Waldron Instil Bio has been a biotech in search of a pipeline after it scrapped its lead assets over the last couple of years. Now, it seems to have found a pair of clinical-stage candidates from China to instill it with new purpose. |
By James Waldron Valneva has added to its growing arsenal of vaccines by handing over 10 million euros ($10.7 million) upfront to LimmaTech for the global license to a Shigella candidate that once formed part of a GSK partnership. |
By James Waldron Otsuka Pharmaceutical has picked up Boston-based Jnana Therapeutics for $800 million so the Japanese biotech can get its hands on a clinical-stage oral phenylketonuria drug. |
By James Waldron OS Therapies will list on the NYSE American stock exchange this morning via a $6.4 million IPO that the biotech will use to push forward with its immunotherapy and antibody-drug conjugate plans. |
By Kevin Dunleavy The launch of Regeneron's Eylea HD has helped the Eylea franchise to a rebound after U.S. sales had declined in each of the previous three quarters. Additionally, Regeneron reported that its FDA decision date on its application for approval of multiple myeloma therapy linvoseltamab is likely to be delayed because of a manufacturing issue. The target date is August 22. |
By Darren Incorvaia While the global incidence of esophageal cancer has increased, so too have the numbers of clinical trials and potential treatments, according to a July 31 report on esophageal cancer released by Novotech. |
By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Gabrielle Masson,Darren Incorvaia,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Conor Hale The FDA officially posted its job opening as it looks to replace Jeff Shuren, who is retiring after 15 years as director. The agency’s vacancy will take applications through August 27. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong highlights some of the most promising companies that made our prestigious Fierce 15 list back in 2014. |
|
|---|
|
|
|
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria. 
|
|
Whitepaper This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
Whitepaper Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
